智能安全监测(3S):多国实施3S概念与原则的经验
3S概念基于药物警戒优先级竞争下需明智投资、聚焦新产品、共享资源并建设国家能力。研究在亚美尼亚、巴西、埃塞俄比亚、印度、秘鲁和泰国针对贝达喹啉、轮状病毒疫苗和他非喹诺酮应用3S原则,通过基线评估和工作计划干预,比较干预前后VigiBase报告数量、完整性评分和结构指标。结果显示多国ADR报告增加、质量改善,部分国家信号检测与风险管理计划评估能力提升。
要点
- 3S原则在六国应用后,亚美尼亚、巴西、印度和埃塞俄比亚的ADR报告数量增加。
- 巴西、秘鲁、泰国和印度的报告质量改善,完整性评分均高于0.5。
- 埃塞俄比亚和印度信号检测与评价能力提升,多国风险管理计划评估能力增强。
核心结论
- 3S概念在六个国家以不同方式展现成功,聚焦三个产品验证概念,预期通过强化系统持续影响。
- 需持续监测以了解当前3S项目的收益和成功是否可持续。
研究设计与样本
- 在亚美尼亚、巴西、埃塞俄比亚、印度、秘鲁和泰国应用3S原则,针对贝达喹啉、轮状病毒疫苗和他非喹诺酮三个优先产品。
- 通过基线药物警戒准备评估识别差距并制定工作计划,比较干预前后VigiBase报告数量、完整性评分和结构指标。
- 实施期为9-18个月,从2018年3月最早开始至2020年5月最晚结束。
主要发现
- 亚美尼亚(贝达喹啉)、巴西(结核病和疟疾药物)、印度(轮状病毒疫苗)和埃塞俄比亚(结核病药物)的ADR报告增加。
- 所有国家基线完整性评分均高于0.5,巴西(结核病)、秘鲁(疟疾)、泰国(疟疾)和印度(免疫接种)的报告质量改善。
- 埃塞俄比亚满足的结构指标数量增加超过一倍。
- 埃塞俄比亚和印度信号检测与信号评价能力提升。
- 亚美尼亚、巴西、秘鲁和泰国实施3S原则后风险管理计划评估能力提升。
临床怎么用
- 3S原则可指导资源有限国家聚焦优先产品,共享工作与资源,建设国家药物警戒能力。
- 通过基线评估识别差距并制定工作计划,以VigiBase报告和结构指标监测干预效果。
局限性
- 实施期较短(9-18个月),需持续监测以评估收益可持续性。
- 仅针对三个产品进行概念验证,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The Smart Safety Surveillance (3S) concept is based on the understanding that, when faced with competing pharmacovigilance priorities, countries will have to invest judiciously, by focusing on new priority products, sharing work and resources with other countries when possible and building national competence for those activities that cannot be delegated. METHOD: The 3S principles were applied to Armenia, Brazil, Ethiopia, India, Peru and Thailand using three priority products: bedaquiline, rotavirus vaccine and tafenoquine. A baseline assessment of pharmacovigilance preparedness was used to identify gaps and establish a work plan. The impact was measured by comparing pre and post 3S-intervention outcomes, which included the number and quality of reports (completeness scores) in the WHO global database of Individual Case Safety Reports, VigiBase, and number of structural indicators met. The implementation period was 9-18 months, ranging from March 2018 (earliest started) until May 2020 (latest). RESULT: An increase in adverse drug reaction (ADR) reporting was demonstrated in Armenia (bedaquiline), Brazil (TB and malaria medicines), India (rotavirus vaccine) and Ethiopia (TB medicines). Completeness scores were above 0.5 at baseline in all countries, and reports improved in quality for Brazil (TB), Peru (malaria), Thailand (malaria) and India (immunization). The number of structural indicators met increased by more than double for Ethiopia. Ethiopia and India demonstrated an increased capacity for signal detection and signal evaluation. Armenia, Brazil, Peru and Thailand showed increased capacity to assess risk management plans following the implementation of 3S principles. CONCLUSION: The 3S concept has demonstrated success in different ways across the six countries. Activities focused on three products for a proof of concept of the 3S principles, with the expectation that the project impact will be sustained through strengthened systems, to guide pharmacovigilance activities of other products in the future. It is important to continue monitoring the countries to understand if the gains and successes of the current 3S project are sustainable.
引用
- Iessa N, Macolic Sarinic V, Ghazaryan L, et al. Smart Safety Surveillance (3S): Multi-Country Experience of Implementing the 3S Concepts and Principles. Drug Saf. 2021. PMID: 34331675. doi:10.1007/s40264-021-01100-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。